Depression and Cardiovascular Disease: An Update on How Course of Illness May Influence Risk

Current Psychiatry Reports

Volumn 16, Issue 10, 2014, Pages

  Fiedorowicz, Jess G ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Bipolar disorder; Cardiovascular diseases; Excess mortality; Inflammation; Major depressive disorder; Vascular stiffness

Indexed keywords

ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; SEROTONIN UPTAKE INHIBITOR;

AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; META ANALYSIS (TOPIC); MORBIDITY; REVIEW; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; COGNITIVE THERAPY; COMPLICATION; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MOOD DISORDERS; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR DISEASES; COGNITIVE THERAPY; DISEASE PROGRESSION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFLAMMATION; MOOD DISORDERS; PITUITARY-ADRENAL SYSTEM; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 84906439511     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-014-0492-6     Document Type: Review

References (98)

1. Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the american heart association. Circulation. 2014;129(12):1350–69. doi:10.1161/CIR.0000000000000019.
2. Wolff HG. Life stress and cardiovascular disorders. Circulation. 1950;1(2):187–203.
3. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122(25):e584–636. doi:10.1161/CIR.0b013e3182051b4c.
4. Frasure-Smith N, Lesperance F. Reflections on depression as a cardiac risk factor. Psychosom Med. 2005;67 Suppl 1:S19–25. doi:10.1097/01.psy.0000162253.07959.db.
5. Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 2007;68(6):899–907.
6. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844–50.
7. Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG. Mania and mortality: why the excess cardiovascular risk in bipolar disorder? Curr Psychiatry Rep. 2009;11(6):475–80.
8. Everson-Rose SA, House JS, Mero RP. Depressive symptoms and mortality risk in a national sample: confounding effects of health status. Psychosom Med. 2004;66(6):823–30. doi:10.1097/01.psy.0000145903.75432.1f.
9. Fiedorowicz JG, He J, Merikangas KR. The association between mood and anxiety disorders with vascular diseases and risk factors in a nationally representative sample. J Psychosom Res. 2011;70(2):145–54. doi:10.1016/j.jpsychores.2010.07.010.
10. Ormel J, Von Korff M, Burger H, Scott K, Demyttenaere K, Huang YQ, et al. Mental disorders among persons with heart disease - results from World Mental Health surveys. Gen Hosp Psychiatry. 2007;29(4):325–34. doi:10.1016/j.genhosppsych.2007.03.009.
11. Meijer A, Conradi HJ, Bos EH, Anselmino M, Carney RM, Denollet J, et al. Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. B J Psychiatry: J Mental Sci. 2013;203:90–102. doi:10.1192/bjp.bp.112.111195.
12. Lesperance F, Frasure-Smith N, Talajic M, Bourassa MG. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation. 2002;105(9):1049–53.
13. Meijer A, Conradi HJ, Bos EH, Thombs BD, van Melle JP, de Jonge P. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. Gen Hosp Psychiatry. 2011;33(3):203–16. doi:10.1016/j.genhosppsych.2011.02.007.
14. Nordentoft M, Wahlbeck K, Hallgren J, Westman J, Osby U, Alinaghizadeh H, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One. 2013;8(1):e55176. doi:10.1371/journal.pone.0055176.
15. Fiedorowicz JG, Solomon DA, Endicott J, Leon AC, Li C, Rice JP, et al. Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med. 2009;71(6):598–606. doi:10.1097/PSY.0b013e3181acee26.
16. Fiedorowicz JG. Jancic D. Butcher B, Coryell WH. Vascular Mortality in Participants of a Bipolar Genomics Study. Psychosomatics: Potash JB; 2014. doi:10.1016/j.psym.2014.02.001.
17. Murray DP, Metz NS, Haynes WG, Fiedorowicz JG. Vascular function is not impaired early in the course of bipolar disorder. J Psychosom Res. 2012;72(3):195–8. doi:10.1016/j.jpsychores.2011.12.006.
18. Sodhi SK, Linder J, Chenard CA, del Miller D, Haynes WG, Fiedorowicz JG. Evidence for accelerated vascular aging in bipolar disorder. J Psychosom Res. 2012;73(3):175–9. doi:10.1016/j.jpsychores.2012.06.004.
19. Fiedorowicz JG, Coryell WH, Rice JP, Warren LL, Haynes WG. Vasculopathy related to manic/hypomanic symptom burden and first-generation antipsychotics in a sub-sample from the collaborative depression study. Psychother Psychosom. 2012;81(4):235–43. doi:10.1159/000334779 000334779.
20. Rajagopalan S, Brook R, Rubenfire M, Pitt E, Young E, Pitt B. Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. The American journal of cardiology. 2001;88(2):196-8, A7.
21. Broadley AJ, Korszun A, Jones CJ, Frenneaux MP. Arterial endothelial function is impaired in treated depression. Heart. 2002;88(5):521–3.
22. Broadley AJ, Korszun A, Abdelaal E, Moskvina V, Deanfield J, Jones CJ, et al. Metyrapone improves endothelial dysfunction in patients with treated depression. J Am Coll Cardiol. 2006;48(1):170–5. doi:10.1016/j.jacc.2005.12.078.
23. Rybakowski JK, Wykretowicz A, Heymann-Szlachcinska A, Wysocki H. Impairment of endothelial function in unipolar and bipolar depression. Biol Psychiatry. 2006;60(8):889–91. doi:10.1016/j.biopsych.2006.03.025.
24. Wagner JA, Tennen H, Mansoor GA, Abbott G. History of major depressive disorder and endothelial function in postmenopausal women. Psychosom Med. 2006;68(1):80–6. doi:10.1097/01.psy.0000195868.68122.9e.
25. Wagner J, Tennen H, Mansoor G, Abbott G. Endothelial dysfunction and history of recurrent depression in postmenopausal women with Type 2 diabetes: a case-control study. J Diabetes Complicat. 2009;23(1):18–24. doi:10.1016/j.jdiacomp.2007.11.007.
26. Greenstein AS, Paranthaman R, Burns A, Jackson A, Malik RA, Baldwin RC, et al. Cerebrovascular damage in late-life depression is associated with structural and functional abnormalities of subcutaneous small arteries. Hypertension. 2010;56(4):734–40. doi:10.1161/HYPERTENSIONAHA.110.152801.
27. Lavoie KL, Pelletier R, Arsenault A, Dupuis J, Bacon SL. Association between clinical depression and endothelial function measured by forearm hyperemic reactivity. Psychosom Med. 2010;72(1):20–6. doi:10.1097/PSY.0b013e3181c2d6b8.
28. Oulis P, Kouzoupis A, Kyrkou K, Masdrakis VG, Georgiopoulos G, Karapoulios E, et al. Reversal of increased arterial stiffness in severely depressed women after 6-week antidepressant treatment. J Affect Disord. 2010;122(1–2):164–6. doi:10.1016/j.jad.2009.08.003.
29. Paranthaman R, Greenstein AS, Burns AS, Cruickshank JK, Heagerty AM, Jackson A, et al. Vascular function in older adults with depressive disorder. Biol Psychiatry. 2010;68(2):133–9. doi:10.1016/j.biopsych.2010.04.017.
30. Garcia RG, Zarruk JG, Barrera C, Pinzon A, Trillos E, Arenas WD, et al. Plasma nitrate levels and flow-mediated vasodilation in untreated major depression. Psychosom Med. 2011;73(4):344–9. doi:10.1097/PSY.0b013e31821566cf.
31. Seldenrijk A, van Hout HP, van Marwijk HW, de Groot E, Gort J, Rustemeijer C, et al. Depression, anxiety, and arterial stiffness. Biol Psychiatry. 2011;69(8):795–803. doi:10.1016/j.biopsych.2010.12.034.
32. Zhuo C, Wang Y, Tian H, Wang X, Chen Y, Mao F. Impairment of endothelial protection by ischemic postconditioning in patients with major depressive disorder. Can J Physiol Pharmacol. 2011;89(9):647–53. doi:10.1139/Y11-063.
33. Wagner JA, Tennen H, Finan PH, White WB, Burg MM, Ghuman N. Lifetime history of depression, type 2 diabetes, and endothelial reactivity to acute stress in postmenopausal women. Int J Behav Med. 2012;19(4):503–11. doi:10.1007/s12529-011-9190-5.
34. Harris KF, Matthews KA, Sutton-Tyrrell K, Kuller LH. Associations between psychological traits and endothelial function in postmenopausal women. Psychosom Med. 2003;65(3):402–9.
35. Sherwood A, Hinderliter AL, Watkins LL, Waugh RA, Blumenthal JA. Impaired endothelial function in coronary heart disease patients with depressive symptomatology. J Am Coll Cardiol. 2005;46(4):656–9. doi:10.1016/j.jacc.2005.05.041.
36. Pizzi C, Manzoli L, Mancini S, Costa GM. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur Heart J. 2008;29(9):1110–7. doi:10.1093/eurheartj/ehn137.
37. Cooper DC, Milic MS, Tafur JR, Mills PJ, Bardwell WA, Ziegler MG, et al. Adverse impact of mood on flow-mediated dilation. Psychosom Med. 2010;72(2):122–7. doi:10.1097/PSY.0b013e3181cdbfc0.
38. Chen H, Zhang L, Zhang M, Song X, Zhang H, Liu Y, et al. Relationship of depression, stress and endothelial function in stable angina patients. Physiol Behav. 2013;118:152–8. doi:10.1016/j.physbeh.2013.05.024.
39. Tomfohr LM, Martin TM, Miller GE. Symptoms of depression and impaired endothelial function in healthy adolescent women. J Behav Med. 2008;31(2):137–43. doi:10.1007/s10865-007-9141-4.
40. Tomfohr LM, Murphy ML, Miller GE, Puterman E. Multiwave associations between depressive symptoms and endothelial function in adolescent and young adult females. Psychosom Med. 2011;73(6):456–61. doi:10.1097/PSY.0b013e3182228644.
41. Osika W, Montgomery SM, Dangardt F, Wahrborg P, Gan LM, Tideman E, et al. Anger, depression and anxiety associated with endothelial function in childhood and adolescence. Arch Dis Child. 2011;96(1):38–43. doi:10.1136/adc.2008.152777.
42. Tiemeier H, Breteler MM, van Popele NM, Hofman A, Witteman JC. Late-life depression is associated with arterial stiffness: a population-based study. J Am Geriatr Soc. 2003;51(8):1105–10.
43. Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med. 2011;73(2):114–26. doi:10.1097/PSY.0b013e31820ad12b.
44. Belvederi Murri M, Pariante C, Mondelli V, Masotti M, Atti AR, Mellacqua Z, et al. HPA axis and aging in depression: systematic review and meta-analysis. Psychoneuroendocrinology. 2014;41:46–62. doi:10.1016/j.psyneuen.2013.12.004.
45. Hatzinger M, Hemmeter UM, Baumann K, Brand S, Holsboer-Trachsler E. The combined DEX-CRH test in treatment course and long-term outcome of major depression. J Psychiatr Res. 2002;36(5):287–97.
46. Rybakowski JK, Twardowska K. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiatr Res. 1999;33(5):363–70.
47. Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt JM. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry. 2010;67(11):1067–74. doi:10.1016/j.biopsych.2009.12.012.
48. Licht CM, Penninx BW, de Geus EJ. To include or not to include? A response to the meta-analysis of heart rate variability and depression. Biol Psychiatry. 2011;69(4):e1. doi:10.1016/j.biopsych.2010.06.034. author reply e3-4.
49. Baumert M, Lambert GW, Dawood T, Lambert EA, Esler MD, McGrane M, et al. Short-term heart rate variability and cardiac norepinephrine spillover in patients with depression and panic disorder. Am J Physiol Heart Circ Physiol. 2009;297(2):H674–9. doi:10.1152/ajpheart.00236.2009.
50. Lambert E, Dawood T, Straznicky N, Sari C, Schlaich M, Esler M, et al. Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure. J Hypertens. 2010;28(3):543–50. doi:10.1097/HJH.0b013e3283350ea4.
51. Scalco AZ, Rondon MU, Trombetta IC, Laterza MC, Azul JB, Pullenayegum EM, et al. Muscle sympathetic nervous activity in depressed patients before and after treatment with sertraline. J Hypertens. 2009;27(12):2429–36. doi:10.1097/HJH.0b013e3283310ece.
52. Barton DA, Dawood T, Lambert EA, Esler MD, Haikerwal D, Brenchley C, et al. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens. 2007;25(10):2117–24. doi:10.1097/HJH.0b013e32829baae7.
53. Veith RC, Lewis N, Linares OA, Barnes RF, Raskind MA, Villacres EC, et al. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry. 1994;51(5):411–22.
54. Baumert M, Lambert GW, Dawood T, Lambert EA, Esler MD, McGrane M, et al. QT interval variability and cardiac norepinephrine spillover in patients with depression and panic disorder. Am J Physiol Heart Circ Physiol. 2008;295(3):H962–H8. doi:10.1152/ajpheart.00301.2008.
55. Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487(7407):325–9. doi:10.1038/nature11260.
56. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve–an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52(4):595–638.
57. Abboud FM, Harwani SC, Chapleau MW. Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. Hypertension. 2012;59(4):755–62. doi:10.1161/HYPERTENSIONAHA.111.186833.
58. Straub RH, Buttgereit F, Cutolo M. Alterations of the hypothalamic-pituitary-adrenal axis in systemic immune diseases - a role for misguided energy regulation. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S23–31.
59. Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs healthy control subjects: a systematic review and meta-analysis. J Psychiatric Res. 2013;47(9):1119–33. doi:10.1016/j.jpsychires.2013.05.018.
60. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–86. doi:10.1097/PSY.0b013e3181907c1b.
61. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–57. doi:10.1016/j.biopsych.2009.09.033.
62. Tsai SY, Yang YY, Kuo CJ, Chen CC, Leu SJ. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect Disord. 2001;64(2–3):185–93.
63. Su KP, Leu SJ, Yang YY, Shen WW, Chou YM, Tsai SY. Reduced production of interferon-gamma but not interleukin-10 in bipolar mania and subsequent remission. J Affect Disord. 2002;71(1–3):205–9.
64. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90(2–3):263–7. doi:10.1016/j.jad.2005.11.015.
65. Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, Leu SJ. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol. 2004;150(1–2):116–22. doi:10.1016/j.jneuroim.2004.01.006.
66. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31(4):952–5. doi:10.1016/j.pnpbp.2007.02.018.
67. Ortiz-Dominguez A, Hernandez ME, Berlanga C, Gutierrez-Mora D, Moreno J, Heinze G, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9(6):596–602. doi:10.1111/j.1399-5618.2007.00493.x.
68. Cunha AB, Andreazza AC, Gomes FA, Frey BN, da Silveira LE, Goncalves CA, et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2008;258(5):300–4. doi:10.1007/s00406-007-0797-0.
69. Brietzke E, Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, Escosteguy Vargas A, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116(3):214–7. doi:10.1016/j.jad.2008.12.001.
70. Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res. 2011;45(12):1608–16. doi:10.1016/j.jpsychires.2011.08.003.
71. Fontoura PC, Pinto VL, Matsuura C, Resende Ade C, de Bem GF, Ferraz MR, et al. Defective nitric oxide-cyclic guanosine monophosphate signaling in patients with bipolar disorder: a potential role for platelet dysfunction. Psychosom Med. 2012;74(8):873–7. doi:10.1097/PSY.0b013e3182689460.
72. Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord. 2012;136(1–2):110–6. doi:10.1016/j.jad.2011.08.022.
73. Barbosa IG, Morato IB, de Miranda AS, Bauer ME, Soares JC, Teixeira AL. A preliminary report of increased plasma levels of IL-33 in bipolar disorder: further evidence of pro-inflammatory status. J Affect Disord. 2014;157:41–4. doi:10.1016/j.jad.2013.12.042.
74. De Berardis D, Conti CM, Campanella D, Carano A, Scali M, Valchera A, et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol. 2008;21(2):319–24.
75. Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom Med. 2003;65(3):347–56.
76. Hiles SA, Baker AL, de Malmanche T, Attia J. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Med. 2012;42(10):2015–26. doi:10.1017/S0033291712000128.
77. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacol: Off Publ Am College of Neuropsychopharmacol. 2011;36(12):2452–9. doi:10.1038/npp.2011.132.
78. Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology. 1997;35(3):123–7.
79. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacol: Off Publ Am College Neuropsychopharmacol. 2000;22(4):370–9. doi:10.1016/S0893-133X(99)00134-7.
80. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology. 2003;170(4):429–33. doi:10.1007/s00213-003-1566-z.
81. O'Brien SM, Scott LV, Dinan TG. Antidepressant therapy and C-reactive protein levels. B J Psychiatry: J Mental Sci. 2006;188:449–52. doi:10.1192/bjp.bp.105.011015.
82. Dawood T, Lambert EA, Barton DA, Laude D, Elghozi JL, Esler MD, et al. Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. Hypertens Res: Off J Japanese Soc Hypertens. 2007;30(4):285–93. doi:10.1291/hypres.30.285.
83. Mackay GM, Forrest CM, Christofides J, Bridel MA, Mitchell S, Cowlard R, et al. Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. Clin Exp Pharmacol Physiol. 2009;36(4):425–35. doi:10.1111/j.1440-1681.2008.05077.x.
84. Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther. 2009;86(5):527–32. doi:10.1038/clpt.2009.121.
85. Chen YC, Lin WW, Chen YJ, Mao WC, Hung YJ. Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediat Inflamm. 2010;2010:573594. doi:10.1155/2010/573594.
86. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA: J Am Med Assoc. 2010;303(1):47–53. doi:10.1001/jama.2009.1943.
87. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger Jr JT, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA: J Am Med Assoc. 2002;288(6):701–9.
88. O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56(9):692–9. doi:10.1016/j.jacc.2010.03.068.
89. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA: J Am Med Assoc. 2003;289(23):3106–16. doi:10.1001/jama.289.23.3106.
90. Honig A, Kuyper AM, Schene AH, van Melle JP, de Jonge P, Tulner DM, et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007;69(7):606–13. doi:10.1097/PSY.0b013e31814b260d.
91. Santangelo A, Testai M, Barbagallo P, Crisafulli C, Grasso S, Manuele S, et al. Use of specific serotonin reuptake inhibitors (SSRIs) (Sertraline or Citalopram) in the treatment of depression reduces the cardiovascular risk in the elderly: evidence from a Sicilian population >80 years recovered in the assisted sanitary residences (RSA). Arch Gerontol Geriatr. 2009;48(3):350–2. doi:10.1016/j.archger.2008.02.014.
92. Davidson KW, Rieckmann N, Clemow L, Schwartz JE, Shimbo D, Medina V, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med. 2010;170(7):600–8. doi:10.1001/archinternmed.2010.29.
93. Vaccarino V, Johnson BD, Sheps DS, Reis SE, Kelsey SF, Bittner V, et al. Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung, and Blood Institute-sponsored WISE study. J Am Coll Cardiol. 2007;50(21):2044–50. doi:10.1016/j.jacc.2007.07.069.
94. Greden JF. The National Network of Depression Centers: progress through partnership. Depression Anxiety. 2011;28(8):615–21. doi:10.1002/da.20862.
95. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62(12):1322–30.
96. Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL. The enduring psychosocial consequences of mania and depression. Am J Psychiatry. 1993;150(5):720–7.
97. Merikangas KR, Ames M, Cui L, Stang PE, Ustun TB, Von Korff M, et al. The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psychiatry. 2007;64(10):1180–8.
98. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11):e1001547. doi:10.1371/journal.pmed.1001547.